BioSpace News Archive

Job Trends

Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Paris, January 11,2023 Sanofi Ventures has announced an additional multi-year commitment from Sanofi, with an increase in capital to more than $750 million to the evergreen venture fund.

January 11, 2023
·
5 min read
Lone Star Bio

PCCA Introduces Innovative New Compounding Base – SuspendIt® Anhydrous

PCCA’s innovative new oral suspending base, SuspendIt Anhydrous, is ideal for active pharmaceutical ingredients that are unstable in water or have incompatibilities with existing aqueous vehicles.

January 11, 2023
·
2 min read
Ice Global Consulting, Inc. Completes Acquisition of Epicenter™ Technology

ICE Global Consulting, Inc. (ICE Global) announced today that it has entered into an asset purchase agreement to acquire all operating assets related to the Epicenter™ contracts management technology from Journey CTS, LLC.

January 11, 2023
·
2 min read
Deals

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc.

January 11, 2023
·
4 min read
Pharm Country

BD Introduces Fully Automated Robotic Track System for Microbiology Labs

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results.

January 11, 2023
·
4 min read
Drug Development

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab.

January 11, 2023
·
3 min read
Drug Development

Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial

Emerald Health Pharmaceuticals Inc. has received a positive safety review following a pre-specified interim analysis by the Safety Review Committee (“SRC”) of its Phase 2a study of EHP-101 for systemic sclerosis (“SSc”).

January 11, 2023
·
6 min read
Drug Development

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

Landos Biopharma, Inc. today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization domain.

January 11, 2023
·
4 min read
Business

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Algernon Pharmaceuticals Inc. is pleased to announce that it has appointed Dr. Peter Dicpinigaitis MD, Professor of Medicine at the Albert Einstein College of Medicine, in New York, as a medical consultant to the Company’s chronic cough research program.

January 11, 2023
·
6 min read
Business

Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for the year ended December 31, 2022.

January 11, 2023
·
7 min read